由于审判失败、裁员和股票价值损失,Alallakos停止了AK006毒品开发。 Allakos halts AK006 drug development due to failed trial, cutting jobs and losing stock value.

Allakos Inc.宣布,其第一阶段AK006用于治疗慢性自发尿道的临床试验并未显示出预期效益。 Allakos Inc. announced that its phase 1 clinical trial of AK006 for treating chronic spontaneous urticaria did not show expected benefits. 该公司将停止AK006的开发,将劳动力削减75%,保留约15名雇员。 The company will halt AK006 development, cutting its workforce by 75% and retaining about 15 employees. 预计重组将耗资3 400万美元至3 800万美元。 The restructuring is expected to cost $34 million to $38 million. Allakos的股票在公告后下降了74.8%。 Allakos' stock dropped 74.8% following the announcement.